

# Nonalcoholic Steatohepatitis: Novel Therapeutic Agents and the Role of Liver Transplantation



Author: Sonali Paul, MD, MS Assistant Professor of Medicine The University of Chicago Medicine

**Disclosure(s):** Dr. Paul and the reviewers who contributed to this activity have no relevant financial relationships of interest to disclose. Dr. Muran is a consultant for Veloxis.

## **Learning Objectives:**

### At the end of this knowledge-based activity, participating individuals should be able to:

- Identify the key role insulin resistance has on the development of NAFLD and why this should be the target of all lifestyle and pharmacological interventions.
- Discuss the role of liver transplant in the management of NAFLD in the context of decompensated cirrhosis or liver cancer and the importance of early referral to a transplant center.
- Discuss the role of medications in the NAFLD management, including vitamin E, pioglitazone, metformin, liraglutide, and semaglutide; in addition to others in the pipeline.

Target Audience: Pharmacists

Type of Activity: Knowledge

Fee: \$10 (or \$35 for all 5 courses). For ITPA 2021 participants who registered for the live program, please use

the access code provided to you by email.

Release Date: October 15, 2021 Expiration Date: October 11, 2023 Estimated time to complete activity: 0.75 hour CE: 0.75 contact hours (0.075 CEUs)

Please visit <a href="https://pharmacyce.uic.edu/moodle/">https://pharmacyce.uic.edu/moodle/</a> to participate in this activity.

**Acknowledgments:** This activity is supported in part by an educational grant by **Sanofi Genzyme**.

#### **Continuing Education Statement:**

The University of Illinois at Chicago College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The non-accredited joint provider for this activity is Illinois Transplant Pharmacists Association. This activity has been assigned ACPE Universal Activity Number 0016-9999-21-080-H01-P, for 0.75 contact hours (0.075 CEUs). Reading the learning objectives and faculty disclosures; participating in the entire knowledge-based activity, active learning activity, post-test and activity evaluation; estimating duration of time spent on the activity; and submitting NABP eProfile ID and MMDD are prerequisites for receiving continuing pharmacy education credits. All ACPE credit awarded to participants must be uploaded to CPE Monitor<sup>TM</sup> within 30 days of the activity date, so pharmacists are required to provide their eProfile ID and date of birth (MMDD) at the time of the activity. Please contact <a href="mailto:pharmac@uic.edu">pharmac@uic.edu</a> if you do not see activity information listed within 30 days. For more information and to set up your e-Profile visit: <a href="mailto:www.MyCPEmonitor.net">www.MyCPEmonitor.net</a>.

#### **How to Earn Credit:**

Participants must complete the activity as described above in the Continuing Education Statement. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on 'Finish Attempt', then click on 'Submit All and Finish' at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test, a confirmation message will appear at the top of the page underneath your grade. You will have a chance to review the correct answers and answer rationale.

Hardware/Software and Internet Requirements can be found at https://pharmacyce.uic.edu/moodle/.

**Provider Contact Information:** For general information please call the Office of Continuing Education and Meeting Services toll-free at (866) PHARM-CE (866-742-7623) or send an e-mail to: <a href="mailto:pharmce@uic.edu">pharmce@uic.edu</a>. Copyright © 2021 – The Board of Trustees of the University of Illinois. All rights reserved. Reproduction in whole or in part without permission is prohibited. <a href="mailto:privacy-policy">Privacy-policy</a>.